[{"id":"3aba5b38-3db1-4e50-b966-dbbd60ad2e6e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863818","created_at":"2025-09-07T01:52:13.355Z","updated_at":"2025-09-07T01:52:13.355Z","phase":"","brief_title":"Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs","source_id_and_acronym":"NCT06863818","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" EGFR • HER-2 • MET • ERBB3 • NRG1 • ERBB4","pipe":"","alterations":" ","tags":["EGFR • HER-2 • MET • ERBB3 • NRG1 • ERBB4"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/10/2022","start_date":" 10/10/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-03-07"},{"id":"2e5ccca8-120c-4e72-b9c4-3d96418121c2","acronym":"NCI-2018-01218","url":"https://clinicaltrials.gov/study/NCT03065387","created_at":"2021-01-18T15:06:02.917Z","updated_at":"2025-02-25T15:25:34.097Z","phase":"Phase 1","brief_title":"Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation","source_id_and_acronym":"NCT03065387 - NCI-2018-01218","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • KRAS • ERBB3 • ERBB4","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification","tags":["HER-2 • KRAS • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 93","initiation":"Initiation: 10/31/2017","start_date":" 10/31/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-10"},{"id":"38f71642-9963-4119-8080-8fd4152ee9d4","acronym":"NCI9922","url":"https://clinicaltrials.gov/study/NCT02581930","created_at":"2021-01-18T12:31:19.061Z","updated_at":"2024-07-02T16:35:02.824Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma","source_id_and_acronym":"NCT02581930 - NCI9922","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • LAG3 • CTLA4 • ERBB4 • CD40","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • LAG3 • CTLA4 • ERBB4 • CD40"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/17/2016","start_date":" 08/17/2016","primary_txt":" Primary completion: 02/10/2018","primary_completion_date":" 02/10/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-05-17"},{"id":"b43bd831-d20e-49e4-b923-6ad5ee195cf2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06361940","created_at":"2024-04-12T13:45:06.917Z","updated_at":"2024-07-02T16:35:09.622Z","phase":"Phase 2","brief_title":"Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer","source_id_and_acronym":"NCT06361940","lead_sponsor":"Medical College of Wisconsin","biomarkers":" EGFR • HER-2 • ERBB3 • ERBB4","pipe":" | ","alterations":" ERBB3 expression • ERBB4 expression","tags":["EGFR • HER-2 • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression • ERBB4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-04-15"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"c5f60531-65fd-4bcb-88b3-780e1307cb1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05512182","created_at":"2022-08-23T14:55:32.104Z","updated_at":"2024-07-02T16:35:45.560Z","phase":"Phase 2","brief_title":"Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression","source_id_and_acronym":"NCT05512182","lead_sponsor":"Yonsei University","biomarkers":" EGFR • HER-2 • ERBB3 • ERBB4","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 negative • ERBB3 mutation • ERBB4 mutation","tags":["EGFR • HER-2 • ERBB3 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 amplification • HER-2 negative • ERBB3 mutation • ERBB4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Nerlynx (neratinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2023-06-15"},{"id":"a20d813c-0be4-46f6-9eac-b9a7b8cfecb6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05187767","created_at":"2022-01-12T15:53:45.698Z","updated_at":"2024-07-02T16:36:00.723Z","phase":"","brief_title":"Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs","source_id_and_acronym":"NCT05187767","lead_sponsor":"University of Roma La Sapienza","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • ROS1 • IDH1 • IDH2 • FGFR3 • FGFR1 • HRAS • PDGFRA • NOTCH1 • SMAD4 • CTNNB1 • ERBB4 • DDR2"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-11-08"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"ae0ae0fc-eef8-44be-b782-08ce8200dcd3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04872985","created_at":"2021-05-05T12:52:57.633Z","updated_at":"2024-07-02T16:36:30.708Z","phase":"Phase 2","brief_title":"Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial","source_id_and_acronym":"NCT04872985","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" EGFR • HER-2 • ERBB4","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["EGFR • HER-2 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 04/20/2021","start_date":" 04/20/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2021-05-05"},{"id":"940999b4-26e1-421e-8288-881184dee00a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04683770","created_at":"2021-01-19T20:47:11.581Z","updated_at":"2024-07-02T16:36:36.846Z","phase":"","brief_title":"Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer","source_id_and_acronym":"NCT04683770","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2 • ER • TP53 • PIK3CA • TMB • CCND1 • ERBB4","pipe":" | ","alterations":" TP53 mutation • HER-2 negative • PIK3CA mutation • HER-2 mutation • PGR expression","tags":["HER-2 • ER • TP53 • PIK3CA • TMB • CCND1 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 negative • PIK3CA mutation • HER-2 mutation • PGR expression"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2020-12-24"},{"id":"8169fcff-ab24-4e73-97e1-0e9ba199e177","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681911","created_at":"2021-01-19T08:30:00.325Z","updated_at":"2024-07-02T16:36:36.931Z","phase":"Phase 2","brief_title":"Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT04681911","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2 • TP53 • TMB • CCND1 • ERBB4","pipe":" | ","alterations":" PIK3CA mutation","tags":["HER-2 • TP53 • TMB • CCND1 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate • Cipterbin (inetetamab)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 09/09/2020","start_date":" 09/09/2020","primary_txt":" Primary completion: 09/09/2023","primary_completion_date":" 09/09/2023","study_txt":" Completion: 09/09/2024","study_completion_date":" 09/09/2024","last_update_posted":"2020-12-23"},{"id":"7fc944c0-52e2-402d-9521-56f61f9ca32e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00320411","created_at":"2021-01-18T01:06:12.786Z","updated_at":"2024-07-02T16:37:03.302Z","phase":"Phase 2","brief_title":"GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer","source_id_and_acronym":"NCT00320411","lead_sponsor":"GlaxoSmithKline","biomarkers":" EGFR • HER-2 • BCL2 • ERBB3 • ERBB4 • BIRC5","pipe":" | ","alterations":" HER-2 overexpression • HER-2 expression","tags":["EGFR • HER-2 • BCL2 • ERBB3 • ERBB4 • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 11/28/2005","start_date":" 11/28/2005","primary_txt":" Primary completion: 04/01/2009","primary_completion_date":" 04/01/2009","study_txt":" Completion: 04/01/2009","study_completion_date":" 04/01/2009","last_update_posted":"2019-01-31"},{"id":"fc773c10-831d-4093-bf18-8c93ac9d8441","acronym":"","url":"https://clinicaltrials.gov/study/NCT00699907","created_at":"2021-01-18T02:37:00.384Z","updated_at":"2024-07-02T16:37:08.718Z","phase":"Phase 2a","brief_title":"Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer","source_id_and_acronym":"NCT00699907","lead_sponsor":"University of Arizona","biomarkers":" BRCA1 • BRCA2 • ERBB4 • CSF1R","pipe":" | ","alterations":" BRCA2 mutation • HER-2 expression • CSF1 expression • ERBB4 expression","tags":["BRCA1 • BRCA2 • ERBB4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • HER-2 expression • CSF1 expression • ERBB4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flutamide"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 01/01/2005","start_date":" 01/01/2005","primary_txt":" Primary completion: 11/01/2012","primary_completion_date":" 11/01/2012","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2018-07-24"},{"id":"38b4ea86-be9b-4593-9561-c706c5419517","acronym":"","url":"https://clinicaltrials.gov/study/NCT00993642","created_at":"2021-01-18T03:52:53.214Z","updated_at":"2025-02-25T15:50:31.130Z","phase":"Phase 1","brief_title":"ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer","source_id_and_acronym":"NCT00993642","lead_sponsor":"Tulane University Health Sciences Center","biomarkers":" ERBB4","pipe":"","alterations":" ","tags":["ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • Farydak (panobinostat)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2009","start_date":" 09/01/2009","primary_txt":" Primary completion: 09/01/2010","primary_completion_date":" 09/01/2010","study_txt":" Completion: 12/01/2010","study_completion_date":" 12/01/2010","last_update_posted":"2017-03-13"},{"id":"ee0966e7-7446-4b63-baf4-47c8eb3df1b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02873390","created_at":"2021-01-18T14:06:26.478Z","updated_at":"2024-07-02T16:37:28.637Z","phase":"Phase 1/2","brief_title":"PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor","source_id_and_acronym":"NCT02873390","lead_sponsor":"Ningbo Cancer Hospital","biomarkers":" EGFR • HER-2 • ERBB4","pipe":" | ","alterations":" EGFR positive","tags":["EGFR • HER-2 • ERBB4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2016-10-07"},{"id":"c5f5bb20-1548-491a-a453-c6edee93709f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02862028","created_at":"2021-01-18T14:02:59.033Z","updated_at":"2024-07-02T16:37:29.568Z","phase":"Phase 1/2","brief_title":"PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)","source_id_and_acronym":"NCT02862028","lead_sponsor":"Shanghai International Medical Center","biomarkers":" EGFR • HER-2 • ERBB4 • IGF1","pipe":" | ","alterations":" EGFR positive","tags":["EGFR • HER-2 • ERBB4 • IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2016-08-25"}]